ENDOPIN - BTB Therapeutics
Alternative Names: BTB-101Latest Information Update: 17 Jul 2025
At a glance
- Originator Kyoto University
- Developer BTB Therapeutics; Kyoto University
- Class Non-opioid analgesics; Small molecules
- Mechanism of Action Alpha 2b adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Postoperative pain
- Preclinical Cancer pain; Pruritus
Most Recent Events
- 17 Jul 2025 Preclinical trials in Cancer pain in Japan (PO) prior to July 2025 (BTB Therapeutics pipeline, July 2025)
- 17 Jul 2025 Preclinical trials in Pruritus in Japan (PO) prior July 2025 (BTB Therapeutics pipeline, July 2025)
- 24 Apr 2024 Adverse events data from phase I/II trial in Postoperative pain released by Kyoto University